Monopar Therapeutics Q1 2024 10-Q: Cash & Investments Detailed

TL;DR

**Monopar Q1 2024 10-Q: $17.5M cash, $14.9M investments. No forfeitures. Options vesting.**

AI Summary

Monopar Therapeutics filed its 10-Q for the period ending March 31, 2024. The company reported cash and cash equivalents of $17,484,175 and investments of $14,904,497. There were no forfeitures or restricted stock units granted during the quarter. The company also noted that 10,000 stock options vest monthly over one year.

Why It Matters

This filing provides a snapshot of Monopar Therapeutics' financial health and operational details for the first quarter of 2024, crucial for investors assessing the company's stability and future prospects.

Risk Assessment

Risk Level: medium — As a clinical-stage biopharmaceutical company, Monopar Therapeutics faces inherent risks related to drug development, regulatory approvals, and market adoption, which are not fully mitigated by its current cash position.

Key Numbers

• $17.5B — Cash and Cash Equivalents (Represents the company's liquid assets as of March 31, 2024.)
• $14.9B — Investments (Indicates the value of the company's longer-term investments as of March 31, 2024.)
• 0 — Forfeitures (No stock option forfeitures occurred in Q1 2024.)
• 0 — Restricted Stock Units Granted (No RSUs were granted in Q1 2024.)

Key Players & Entities

• Monopar Therapeutics (company) — Filer of the 10-Q
• March 31, 2024 (date) — End of reporting period
• $17,484,175 (dollar_amount) — Cash and cash equivalents as of March 31, 2024
• $14,904,497 (dollar_amount) — Investments as of March 31, 2024
• 10,000 (dollar_amount) — Stock options vesting monthly over one year

FAQ

From the Filing

0001437749-24-015454.txt : 20240509 0001437749-24-015454.hdr.sgml : 20240509 20240509070058 ACCESSION NUMBER: 0001437749-24-015454 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 52 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240509 DATE AS OF CHANGE: 20240509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Monopar Therapeutics CENTRAL INDEX KEY: 0001645469 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320463781 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39070 FILM NUMBER: 24928471 BUSINESS ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 BUSINESS PHONE: 8473880349 MAIL ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 10-Q 1 mnpr20240331_10q.htm FORM 10-Q mnpr20240331_10q.htm 0001645469 Monopar Therapeutics Inc. false --12-31 Q1 2024 0.001 0.001 40,000,000 40,000,000 17,484,175 17,484,175 14,904,497 14,904,497 81,932 37,661 17,484,175 0.001 5.00 5.01 10.00 10.01 15.00 15.01 20.00 false false false false There were no forfeitures during the three months ended March 31, 2024. Cash equivalents as of March 31, 2024 and December 31, 2023, represent the fair value of the Company’s investment in two money market accounts and U.S. Treasury Bills with maturities at the date of purchase of three months or less. There were no restricted stock units granted during the three months ended March 31, 2024. 10,000 options vest as follows: options to purchase 10,000 shares of the Company’s common stock vest monthly over one year. Forfeitures only include known forfeitures to-date as the Company accounts for forfeitures as they occur due to a limited history of forfeitures. Investments represents the fair value of the Company’s investment in U.S. Treasury Bills with maturities at the date of purchase over three months to one year. 0001645469 2024-01-01 2024-03-31 xbrli:shares 0001645469 2024-04-30 thunderdome:item iso4217:USD 0001645469 2024-03-31 0001645469 2023-12-31 iso4217:USD xbrli:shares 0001645469 2023-01-01 2023-03-31 0001645469 us-gaap:CommonStockMember 2023-12-31 0001645469 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001645469 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001645469 us-gaap:RetainedEarningsMember 2023-12-31 0001645469 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001645469 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001645469 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001645469 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001645469 us-gaap:ShareBasedPaymentArrangementEmployeeMember us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001645469 us-gaap:ShareBasedPaymentArrangementEmployeeMember us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001645469 us-gaap:ShareBasedPaymentArrangementEmployeeMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001645469 us-gaap:ShareBasedPaymentArrangementEmployeeMember us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001645469 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2024-01-01 2024-03-31 0001645469 us-gaap:CommonStockMember 2024-03-31 0001645469 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001645469 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001645469 us-gaap:RetainedEarningsMember 2024-03-31 0001645469 us-gaap:CommonStockMember 2022-12-31 0001645469 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001645469 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001645469 us-gaap:RetainedEarningsMember 2022-12-31 0001645469 2022-12-31 0001645469 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001645469 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001645469 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001645469 us-gaap:RetainedEarnin